Immunomodulation of innate immune responses by vasoactive intestinal peptide (VIP): its therapeutic potential in inflammatory disease

Smalley, S G R; Barrow, Paul; Foster, Neil

doi:10.1111/j.1365-2249.2009.03956.x

Cited by 56 publications

(52 citation statements)

References 89 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the immune system, VIP can modulate both innate and adaptive immunity, showing predominantly anti-inflammatory and immunomodulatory actions. In vivo mouse data indicate that VIP treatment may have a promising role in the treatment of inflammatory and autoimmune diseases (Delgado, 2001;Gomariz, 2006;Lodde, 2006;Arranz, 2008;Calafat, 2009;Smalley, 2009;Gomariz, 2010). In several animal models of inflammation and autoimmune diseases, it has been described that VIP decreases cytokine expressions related to Th17 cells (Abad, 2005;Leceta, 2007;Jimeno, 2010).…”

Section: Introductionmentioning

confidence: 99%

Vasoactive Intestinal Peptide Maintains the Nonpathogenic Profile of Human Th17-Polarized Cells

et al. 2014

View full text Add to dashboard Cite

The cytokine microenvironment modulates CD4 T cell differentiation causing the shift of naïve CD4 T cells into different cell subsets. This process is also regulated by modulators such as VIP, a neuropeptide with known immunomodulatory properties on CD4 T cells that exert this action through specific receptors, VPAC 1 and VPAC 2 . Our results show that the pattern of VIP receptors expression ratio is modified during Th17 differentiation. In this report, we evaluate the capacity of VIP to modulate naïve human cells into

show abstract

Section: Introductionmentioning

confidence: 99%

Vasoactive Intestinal Peptide Maintains the Nonpathogenic Profile of Human Th17-Polarized Cells

et al. 2014

View full text Add to dashboard Cite

show abstract

“…We here found that lowest levels of CGRP and VIP in kidney tissues were found in papillary RCC. In addition to its direct anti-tumoral effects [29], VIP and analogues are considered for treatment of autoimmune and inflammatory diseases [35]. Hence local inhibition of peptidergic system in papillary type RCC may partly be responsible from resistance to immunotherapy.…”

Section: Discussionmentioning

confidence: 99%

Neuropeptide Levels as well as Neprilysin Activity Decrease in Renal Cell Carcinoma

Erin

Ipekci

Akkaya

et al. 2016

Cancer Microenvironment

View full text Add to dashboard Cite

Calcitonin Gene-related Peptide (CGRP), Vasoactive Intestinal Peptide (VIP) and Substance P (SP) are sensory neuropeptides which may alter cancer growth through modulation of chronic inflammation. We recently reported that SP suppresses breast cancer growth and metastasis through neuroimmune modulation. These neuropeptides are hydrolyzed by Neprilysin (NEP) to bioactive fragments. Decreased activity of NEP was reported in clear cell and chromophobe type renal cell carcinoma (RCC). It is however not known how the levels of neuropeptides hydrolyzed with NEP changes in RCC. Decrease activity of SP and CGRP containing sensory nerve endings was previously reported to increase cancer metastasis in animal models. It is however not known how peptidergic nerve endings are altered in RCC. Hence we here evaluated the levels of neuronal and non-neuronal neuropeptides and NEP activity in RCC including papillary type as well as neighboring uninvolved kidney. A cross-sectional study was conducted in 57 patients undergoing radical nephrectomy and diagnosed with RCC. NEP activity, levels and expression were determined using flourogenic substrate, western blot and qPCR respectively in freshly-frozen tissues. Immunohistochemical analyses were also performed.Neuronal and non-neuronal levels of CGRP, SP and VIP levels were determined using two-step acetic acid extraction. Levels and activity of NEP were markedly decreased in RCC regardless of subtype. Similar levels of VIP were detected in first and second extractions. VIP levels were higher in clear cell and papillary RCC compared to nearby kidney tissue. VIP levels of neighboring kidney tissue of papillary type RCC was significantly lower compared to kidney samples from clear cell RCC. CGRP levels were higher in second extraction. Similar to VIP levels, CGRP levels of neighboring kidney tissue from clear cell and chromophobe type RCC was significantly lower compared to corresponding tumor samples, an effect observed in the second extraction. VIP and CGRP levels of nearby kidney tissue varied subtype dependently demonstrating that different subtypes of RCC alter their local environment differently. Furthermore NEP-induce hydrolysis of VIP creates selective VPAC-1 receptor agonist which has anti-proliferative and anti-inflammatory effects. Hence loss of NEP activity may prevent antitumoral effects of VIP on RCC.

show abstract

“…Meanwhile, studies have also identified a pathway that inhibits nuclear entry of NF-κB through VPAC signaling, which inhibits IκB phosphorylation (cAMP-independent pathway). shows a graphical representation of VIP signal transmission and the expected regulatory activity of the inflamematory reactions [47,48].…”

Section: Signal Transductionmentioning

confidence: 99%

Vasoactive Intestinal Peptide (VIP) and VIP Receptors-Elucidation of Structure and Function for Therapeutic Applications

Igarashi¹,

Fujimori²,

Ito³

et al. 2011

IJCM

View full text Add to dashboard Cite

show abstract

Immunomodulation of innate immune responses by vasoactive intestinal peptide (VIP): its therapeutic potential in inflammatory disease

Cited by 56 publications

References 89 publications

Vasoactive Intestinal Peptide Maintains the Nonpathogenic Profile of Human Th17-Polarized Cells

Vasoactive Intestinal Peptide Maintains the Nonpathogenic Profile of Human Th17-Polarized Cells

Neuropeptide Levels as well as Neprilysin Activity Decrease in Renal Cell Carcinoma

Vasoactive Intestinal Peptide (VIP) and VIP Receptors-Elucidation of Structure and Function for Therapeutic Applications

Contact Info

Product

Resources

About